이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Exagen 배당금

배당금 기준 확인 0/6

Exagen 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.11
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 XGN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: XGN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Exagen 시장 대비 배당 수익률

XGN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (XGN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (XGN)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XGN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XGN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XGN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: XGN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Exagen 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Consensus estimates of losses per share improve by 13%

CEO, President & Director recently bought US$78k worth of stock

Exagen Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q1, 2024 Results on May 13, 2024

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024

Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 11%

Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.0% to US$5.75

CEO, President & Director recently sold US$59k worth of stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023

Exagen Inc. Appoints Paul Kim as Class II Director

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$1.92 loss, revenue downgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 38% to US$6.50

Exagen Inc. Announces Board Changes

Exagen Inc. Announces Executive Changes

Exagen Inc. Increases Revenue Guidance for 2022

Exagen Inc. announced delayed 10-Q filing

Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022

Exagen Inc. Appoints John Aballi as President

Exagen appoints John Aballi as CEO

Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation Officer

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Price target decreased to US$12.25

Consensus revenue estimates fall by 19%

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen Inc. Provides Revenue Guidance for the Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target decreased to US$16.40

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. Revises Revenue Guidance for the Full Year of 2022

Price target decreased to US$18.00

Exagen Inc. to Report Q1, 2022 Results on May 11, 2022

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Consensus EPS estimates fall by 12%

Price target decreased to US$21.00

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science Medicine

Price target increased to US$26.75

Independent Director Jeffrey Elliott has left the company

Independent Director Jeffrey Elliott has left the company

Consensus forecasts updated

First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)

Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Consensus EPS estimates fall to -US$1.52

Price target increased to US$27.00

Full year 2020 earnings released: US$1.32 loss per share (vs US$8.46 loss in FY 2019)

Exagen Inc. Provides Revenue Guidance for the Full Year 2021

Exagen Inc. to Report Q4, 2020 Results on Mar 16, 2021

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

New 90-day high: US$19.56

New 90-day high: US$17.00

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Exagen issues preliminary testing revenue ahead of ICT chat

New 90-day high: US$16.10